Literature DB >> 12672403

Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.

Lionel G Filion1, Darius Matusevicius, Gina M Graziani-Bowering, Ashok Kumar, Mark S Freedman.   

Abstract

Multiple sclerosis has been postulated to be an autoimmune disease in which Th1 immune responses predominate. This response is associated with an increased production of IFNgamma and IL12 produced by T cells and by cells of the monocyte (MO) lineage, respectively. An increased expression of costimulatory molecules by T cells and antigen-presenting cells is also observed. We hypothesized that in relapsing-remitting MS (RRMS) (with or without of IFNbeta treatment) and in secondary progressive patients (SPMS) IL12 and costimulatory molecules (CD80 [B7-1], CD86 [B7-2], CD28, CD40, CD40L) would be differentially produced or expressed by MO or T cells. We performed cross-sectional and longitudinal flow cytometric studies (at monthly intervals) on peripheral blood mononuclear cells (PBMC) or on MO from SPMS or untreated and IFNbeta-treated patients with RRMS. We determined that CD86 and CD40L expression was highest on MO derived from SPMS patients compared to those from RRMS or from healthy controls (HC). In vitro culture of PBMC with recombinant human IL10, a cytokine that may be increased in response to treatment with IFNbeta and that down-regulates CD86 expression, reduced the expression of CD86 on MO derived from RRMS patients to a much higher degree compared to cells derived from SPMS or HC. In vitro secreted IL12 levels from freshly isolated MO from SPMS patients were more than 10-fold higher than either the treated or the untreated RRMS or HC. RRMS patients treated with IFNbeta demonstrated slightly lower levels of MO IL12 secretion. Our data suggest that a key mechanism in the pathogenesis of MS is the increased expression of CD86 and CD40L and the increased production of IL12 during disease progression. Part of the mechanism of action of IFNbeta may be to reduce MO CD86 and CD40L expression and IL12 secretion; failure to do so might signify either a lack of response or a transition to a more progressive phase of illness.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672403     DOI: 10.1016/s1521-6616(02)00028-1

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  18 in total

1.  Monocyte-derived cytokines in multiple sclerosis.

Authors:  L G Filion; G Graziani-Bowering; D Matusevicius; M S Freedman
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

2.  Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas.

Authors:  Anna Bolduc; Eugene Long; Dale Stapler; Marilia Cascalho; Takeshi Tsubata; Pandelakis A Koni; Michiko Shimoda
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

3.  CD40 Signaling in Graves Disease Is Mediated Through Canonical and Noncanonical Thyroidal Nuclear Factor κB Activation.

Authors:  Hanna J Lee; Angela Lombardi; Mihaela Stefan; Cheuk Wun Li; William B Inabnet; Randall P Owen; Erlinda Concepcion; Yaron Tomer
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

4.  Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.

Authors:  Amanda K Huber; Lu Wang; Peisong Han; Xu Zhang; Sven Ekholm; Ashok Srinivasan; David N Irani; Benjamin M Segal
Journal:  Neurology       Date:  2014-09-24       Impact factor: 9.910

Review 5.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

6.  GM-CSF Promotes Chronic Disability in Experimental Autoimmune Encephalomyelitis by Altering the Composition of Central Nervous System-Infiltrating Cells, but Is Dispensable for Disease Induction.

Authors:  Patrick C Duncker; Joshua S Stoolman; Amanda K Huber; Benjamin M Segal
Journal:  J Immunol       Date:  2017-12-29       Impact factor: 5.422

Review 7.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

Review 8.  Immunogenetics of autoimmune thyroid diseases: A comprehensive review.

Authors:  Hanna J Lee; Cheuk Wun Li; Sara Salehi Hammerstad; Mihaela Stefan; Yaron Tomer
Journal:  J Autoimmun       Date:  2015-07-30       Impact factor: 7.094

Review 9.  Update on CD40 and CD154 blockade in transplant models.

Authors:  Tianshu Zhang; Richard N Pierson; Agnes M Azimzadeh
Journal:  Immunotherapy       Date:  2015-08-13       Impact factor: 4.196

10.  Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.

Authors:  Jeppe Romme Christensen; Lars Börnsen; Rikke Ratzer; Fredrik Piehl; Mohsen Khademi; Tomas Olsson; Per Soelberg Sørensen; Finn Sellebjerg
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.